Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Prevalence and clinical significance of anti-ribosomal P antibody in childhood-onset systemic lupus erythematosus

Full text
Author(s):
Aldar, H. [1] ; Lapa, A. T. ; Bellini, B. ; Sinicato, N. A. ; Postal, M. [5] ; Fernandes, P. T. ; Costallat, L. T. L. [7] ; Marini, R. [8] ; Appenzeller, S. [9]
Total Authors: 9
Affiliation:
[1] Univ Estadual Campinas. Dept Med
[5] Univ Estadual Campinas. Dept Med
[7] Univ Estadual Campinas. Dept Med
[8] Univ Estadual Campinas. Dept Pediat
[9] Univ Estadual Campinas. Dept Med
Total Affiliations: 9
Document type: Journal article
Source: Lupus; v. 21, n. 11, p. 1225-1231, OCT 2012.
Web of Science Citations: 4
Abstract

Objective: To investigate the prevalence of the anti-ribosomal P (anti-P) antibodies in childhood-onset systemic lupus erythematosus patients (cSLE), healthy controls and first degree relatives. To elucidate the association between anti-P and disease activity, laboratory and treatment features in cSLE patients. Methods: We included consecutive SLE patients with disease onset before 16 years. Controls were age- and sex-matched. SLE patients were assessed for clinical and laboratory SLE manifestations, disease activity (SLE Disease Activity Index (SLEDAI)), damage (Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI)) and current drug exposures. Mood disorders were determined through Becks Depression and Becks Anxiety Inventory. Anti-P measured by enzyme-linked immunosorbent assay. Results: We included 50 consecutive cSLE patients (mean age of 16.82 +/- 3.46 years), 35 first degree relatives (mean age of 38.73 +/- 3.89 years) and 20 health control (mean age of 18.3 +/- 4.97 years). Anti-P was observed in 13 (26%) cSLE patients and in no first-degree relative (p < 0.01) or control (p < 0.01). Anti-P was more frequently observed in patients with anxiety (p < 0.002). No other clinical, laboratory or treatment features, including SLEDAI and SDI scores were associated with the presence of anti-P in cSLE patients. Conclusion: Anti-P is frequently observed in cSLE patients and was associated with the presence of anxiety in this cohort of cSLE. Lupus (2012) 21, 1225-1231. (AU)

FAPESP's process: 08/02917-0 - Blood and cerebrospinal fluid biomarkers associated with structural and functional central nervous system abnormalities in systemic lupus erythematosus
Grantee:Simone Appenzeller
Support type: Research Grants - Young Investigators Grants
FAPESP's process: 09/06049-6 - Blood and cerebrospinal fluid biomarkers associated with structural and functional central nervous system abnormalities in Systemic lupus erythematosus
Grantee:Simone Appenzeller
Support type: Scholarships in Brazil - Young Researchers
FAPESP's process: 09/13046-3 - Analysis of the prevalence of anti-P, anti-NR2 antibodies and the neuronal marker S100 beta in sistemic lupus erythematosus.
Grantee:Henrique Aldar
Support type: Scholarships in Brazil - Master